Embracing European Reference Networks for patient engagement

Maintaining the voice of rare diseases in a new, virtual world: Insights from the European Conference on Rare Diseases (ECRD) 2020

Embracing European Reference Networks (ERNs) for patient engagement

Awareness of ERNs and education around their potential involvement needs to be a core focus to ensure that patients are at the centre of drug and trial development. Alpharmaxim have a deep understanding of the field of rare diseases and the challenges faced by patients in this unique area.

Patients are at the heart of the focus of ERNs
It can be challenging for patient groups and organisations to access ERNs
Involving ERNs and patients at the earliest stage in the drug development process will help to ensure that patient-reported outcomes are realistic and achievable, ensuring that patient outcomes are improved

Be prepared to truly demonstrate your commitment to the rare disease field, particularly in these uncertain times.

“This is a good time for us to try and ride the wave of greater solidarity and think about our fellow people and trying to support everybody, even if they have no condition.”

Victoria Hedley, Rare Disease Policy Manager, Newcastle University

Talk to us about how we can transform your communications

Why Plain Language Summaries are vital in rare disease communications

Plain language summaries can translate complex science for different audiences. But what are they, and how do they improve awareness?

What can COVID-19 campaigns tell us about increasing vaccine uptake?

We examine what lessons we can take from the COVID-19 vaccine campaigns, and how behavioural science insights may help to drive vaccine uptake.

Transforming the rare disease landscape

Over the coming months, we’ll be looking at how new, tailored approaches to communications could help transform the rare disease landscape.